Bristol-Myers Squibb Company Ce (CELG-RI) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysts estimate Earnings Per Share (EPS) of $0.92 and revenue of $47.51B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-4.41 vs est $0.92 (missed -581.8%). 2025: actual $3.47 vs est $6.11 (missed -43.2%). Analyst accuracy: 2%.
EPS Estimates — CELG-RI
2%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$4.41
vs Est $0.92
▼ 120.8% off
2025
Actual $3.47
vs Est $6.11
▼ 76.2% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. EPS trend is improving.
Revenue Estimates — CELG-RI
99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $48.300B
vs Est $47.513B
▲ 1.6% off
2025
Actual $48.194B
vs Est $47.990B
▲ 0.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
